Transparency about side effects is a non-negotiable part of any honest health product. If you are considering NAD+ injection therapy, you deserve a clear, accurate, and complete picture of what to expect — not a sanitised marketing version.

This article covers the full side effect profile of subcutaneous NAD+ injection: what is common, what is rare, what is normal, and what warrants attention. It is written to the standard that healthcare professionals apply to informed consent — because you deserve nothing less.

The Established Safety Profile of NAD+

NAD+ has been studied in clinical settings for decades. Intravenous NAD+ therapy has been used since the 1960s. Human clinical trials of NAD+ precursors and injectable NAD+ have collectively enrolled thousands of participants, and the published literature shows a consistent pattern: NAD+ therapy has an excellent safety profile, with adverse events that are predominantly mild, temporary, and site-related.

No serious adverse events have been attributed to NAD+ itself at therapeutic doses in any published clinical literature. NAD+ is an endogenous molecule — your body produces and uses it constantly. You are replenishing a molecule integral to your own physiology, not introducing a foreign pharmacological compound.

<5% Rate of significant adverse events

0 Serious adverse events in published trials

~95% Users complete protocol without notable issues

24–48h Duration of most transient effects

 

Common Side Effects (Experienced by Some Users)

1. Injection Site Reaction

The most frequently reported experience is a small, temporary raised bump (wheal) at the injection site, sometimes accompanied by mild redness or warmth. This is a normal subcutaneous tissue response to fluid introduction — not an allergic reaction. It typically resolves within 15–30 minutes and is entirely harmless.

How to minimise: Rotate injection sites with every dose. Allow alcohol swab (if used) to dry completely before injecting. Apply gentle pressure after injection without rubbing.

2. Temporary Fatigue on Day 1–2

A small minority of users — particularly those with severely depleted baseline NAD+ levels — report feeling mildly tired or 'heavy' on the first day or two of the loading protocol. This is consistent with a rapid upregulation of cellular metabolic activity as NAD+ availability suddenly increases. Cells that have been functioning in a depleted state must adjust to the new availability.

This effect, when it occurs, is almost always resolved by day 3 and does not recur during the maintenance phase. It is a sign the therapy is working, not that something is wrong.

3. Increased Thirst

Increased thirst during the loading phase is reported by some users. The mechanism relates to elevated cellular metabolic activity increasing intracellular water demand. It is mild and easily managed: maintain good hydration (2–3 litres of water per day) during and after the loading phase.

4. Mild Headache

Occasionally reported, particularly during the loading phase. Likely related to the metabolic upregulation effect and typically resolves within a few hours. Adequate hydration significantly reduces the likelihood and severity of this effect.

Uncommon Side Effects (Reported by a Small Minority)

5. Mild Flushing or Skin Warmth

Occasionally reported, more commonly associated with rapid IV infusion than subcutaneous injection. If experienced with subcutaneous delivery, it is typically brief and mild. It is not a cause for concern, but worth noting if it occurs so you can flag it to a healthcare provider if it persists.

6. Nausea

Rarely reported with subcutaneous delivery. More commonly associated with IV infusion administered too quickly. If nausea occurs with subcutaneous injection, it is typically very mild and brief. If it persists beyond 24 hours or is severe, discontinue and consult a healthcare professional.

7. Mild Bruising at Injection Site

Occasional small bruises at the injection site are not uncommon with any subcutaneous injection, particularly if a small superficial blood vessel is nicked during the injection. This is harmless and typically resolves within a few days. Rotating injection sites with every dose reduces frequency significantly.

What Is NOT Associated with NAD+ Therapy

To address common concerns from people researching NAD+ therapy:

•       NAD+ injection is NOT associated with dependence, tolerance, or withdrawal effects. It is not pharmacologically addictive through any established mechanism.

•       NAD+ is NOT associated with organ toxicity (liver, kidney, heart) at therapeutic doses in any published literature.

•       NAD+ does NOT interact with the majority of common medications through established pharmacological pathways, though informing your GP of any new therapy is always recommended as general practice.

•       Subcutaneous NAD+ is NOT associated with the cardiovascular or respiratory side effects occasionally reported with very rapid IV infusion — because subcutaneous delivery produces a slower, sustained absorption curve rather than an immediate systemic bolus.

All NADvance products are manufactured in MHRA-approved, GMP-certified facilities. Every batch is independently tested for purity, sterility, and concentration before release. Full manufacturing details at nadvance.eu/pages/pen.

Who Should Exercise Additional Caution

Group	Recommendation	Reason
Pregnant or breastfeeding women	Consult doctor before use	Insufficient safety data in pregnancy/lactation
Active cancer patients	Consult oncologist before use	NAD+ supports cellular proliferation — context-dependent risk
Significant cardiovascular disease	Seek medical advice	Precautionary — no established contraindication
Significant renal or hepatic impairment	Seek medical advice	Altered pharmacokinetics possible
Children under 18	Not recommended	No paediatric safety data published
People on prescription medications	Inform your GP	General precaution, not a specific contraindication

 

Safe Injection Practice: Reducing All Risks

•       Always wash hands thoroughly with soap and water for 20+ seconds before handling the pen

•       Inspect the solution before every injection — do not use if cloudy, discoloured, or containing visible particles

•       Rotate injection sites with every dose — abdomen, outer thigh, and upper buttock

•       Allow injection site to dry completely if you use an alcohol swab before injecting

•       Dispose of used pen needles in an approved sharps container immediately after use — never recap used needles

•       Store the pen correctly per the product guidelines — temperature and light exposure affect product integrity

Complete safe use guidance is available at nadvance.eu/pages/instructions — read this before your first injection. Common questions answered at nadvance.eu/pages/faq.

Frequently Asked Questions

Q: What are the most common side effects of NAD+ injection? A: The most common experience is a small, temporary bump or mild redness at the injection site — normal and resolves within 30 minutes. Some users experience mild temporary fatigue or increased thirst during the 3-day loading phase. These are not adverse effects but normal responses to cellular upregulation as NAD+ levels rapidly increase.

 

Q: Are NAD+ injections safe for long-term use? A: All published clinical trials to date show no evidence of adverse effects from ongoing therapeutic NAD+ use. NAD+ is an endogenous molecule; long-term supplementation through injectable routes has an excellent safety profile across all published human data.

 

Q: Can NAD+ injections cause an allergic reaction? A: True allergic reactions to NAD+ are not reported in published literature. Mild injection-site reactions (redness, small wheal) are normal subcutaneous tissue responses, not allergic reactions. If you experience hives, widespread rash, difficulty breathing, or systemic symptoms following injection, seek medical attention promptly.

 

Q: I felt tired after my first injection — is something wrong? A: No. Mild temporary fatigue on day 1 or 2 of the loading phase is reported by a small minority of users and reflects a normal metabolic adjustment response — cells upregulating activity as NAD+ availability suddenly increases. It resolves within 24–48 hours and does not recur. Continue the protocol and ensure adequate hydration and rest.

Questions about your specific health context and NAD+ safety? Our FAQ at nadvance.eu/pages/faq covers medical queries in detail. Order the NADvance pen with confidence at nadvance.eu/products/nadvance-pen-1000mg.